JPET xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] --
QUICK SEARCH:   [advanced]


     

Journal of Pharmacology And Experimental Therapeutics Fast Forward
First published on February 20, 2007; DOI: 10.1124/jpet.106.117572

This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jpet.106.117572v1
321/2/791    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Author home page(s):
Zaijie Jim Wang
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tang, L.
Right arrow Articles by Wang, Z. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tang, L.
Right arrow Articles by Wang, Z. J.


Received for publication November 28, 2006.
Revised February 12, 2007.
Accepted for publication February 13, 2007.

Antinociceptive pharmacology of N-(4-chlorobenzyl)-N'-(4-hydroxy-3-iodo-5-methoxybenzyl) thiourea (IBTU), a high-affinity competitive antagonist of the transient receptor potential vanilloid 1 receptor

Lei Tang 1, Yan Chen 1, Zili Chen 1, Peter M. Blumberg 2, Alan P. Kozikowski 1, Zaijie Jim Wang 3*

1 UIC 2 NIH 3 University of Illinois

* Address correspondence to: E-mail: zjwang{at}uic.edu

Abstract

The transient receptor potential vanilloid 1 receptor (TRPV1) is expressed predominantly in a subset of primary afferent nociceptors. Due to its specific anatomical location and its pivotal role as a molecular integrator for noxious thermal and chemical stimuli, there is a considerable interest to develop TRPV1 antagonists for the treatment of pain. Recently, IBTU (N-(4-chlorobenzyl)-N'-(4-hydroxy-3-iodo-5-methoxybenzyl) thiourea) was synthesized and found in vitro to be a high-affinity competitive antagonist of cytoplasmic, but not intracellular, TRPV1. In this study, we examined the in vivo antinociceptive activity of IBTU in several acute and inflammatory pain models in mice. Our emphasis was on nociceptive pathways that are likely mediated by TRPV1, including capsaicin-, noxious heat-, and proton (including inflammation)-induced nociception tests. Capsazepine was used as a positive control in these experiments. IBTU dose-dependently blocked the capsaicin-induced nociception, confirming its antagonism at TRPV1 in vivo. By itself, IBTU produced significant antinociception as it significantly prolonged the tail-flick latency in a dose-dependent manner. IBTU also blocked both early and late phases of the formalin-induced flinching response as well as acetic acid induced writhing behavior. Moreover, IBTU inhibited the CFA-induced persistent hyperalgesia. Taken together, these data demonstrate that IBTU acts as a TRPV1 antagonist in vivo and suggest that it may be of therapeutic use for the treatment of pain.


Key words: TRPV1, VR1, capsaicin, inflammation, pain, vanilloid


This article has been cited by other articles:


Home page
 J. Biol. Chem.Home page
Y. A. Andreev, S. A. Kozlov, S. G. Koshelev, E. A. Ivanova, M. M. Monastyrnaya, E. P. Kozlovskaya, and E. V. Grishin
Analgesic Compound from Sea Anemone Heteractis crispa Is the First Polypeptide Inhibitor of Vanilloid Receptor 1 (TRPV1)
J. Biol. Chem., August 29, 2008; 283(35): 23914 - 23921.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
S. G. Lehto, R. Tamir, H. Deng, L. Klionsky, R. Kuang, A. Le, D. Lee, J.-C. Louis, E. Magal, B. H. Manning, et al.
Antihyperalgesic Effects of (R,E)-N-(2-Hydroxy-2,3-dihydro-1H-inden-4-yl)-3-(2-(piperidin-1-yl)-4-(trifluoromethyl)phenyl)-acrylamide (AMG8562), a Novel Transient Receptor Potential Vanilloid Type 1 Modulator That Does Not Cause Hyperthermia in Rats
J. Pharmacol. Exp. Ther., July 1, 2008; 326(1): 218 - 229.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
F. Luo, C. Yang, Y. Chen, P. Shukla, L. Tang, L. X. Wang, and Z. J. Wang
Reversal of Chronic Inflammatory Pain by Acute Inhibition of Ca2+/Calmodulin-Dependent Protein Kinase II
J. Pharmacol. Exp. Ther., April 1, 2008; 325(1): 267 - 275.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] --
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 2007 by the American Society for Pharmacology and Experimental Therapeutics.